Skip to main content

Table 1 Baseline characteristics and summary of findings from data of the 80 patients analysed in the study.

From: Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

Variable All GG GT TT
Age (years) 37.5 (SD:9.0),(n = 80) 38.0 (SD:8.5),(n = 29) 37 (SD:9.0),(n = 33) 33.5 (SD:10.2),(n = 18)
Sex Male: 20 Female: 60 Male: 8 Female:21 Male:7 Female:26 Male: 5 Female:13
BMI (kg/m2) 22.6 (SD: 3.6),(n = 80) 22.4 (SD:3.9), (n = 29) 23.2 (SD:3.4), (n = 33) 22 (SD:3.0),(n = 18)
Initial CD4 count (×106 l) 128.5 (IQR:142),(n = 80) 113 (IQR:114),(n = 29) 131(IQR:148),(n = 33) 158 (IQR:9),(n = 18)
Initial viral load(copies/ml) 86450 (IQR:2.3 × 106),(n = 76) 96600 (IQR:2.2 × 106),(n = 27) 84900 (IQR:2.4 × 106),(n = 33) 86500 (IQR:2.1 × 106),(n = 16)
Presence of side effects(%) 84 (n = 67) * 76 (n = 22) 85 (n = 28) 94 (n = 17)
EFV concentrations (μg/l) 3980 (IQR:4476),(n = 80)* 2260 (IQR:3411),(n = 29) ** 3858(IQR:2385),(n = 33)** 7136(IQR:3623),(n = 18)**
  1. IQR: interquartile range
  2. n = number
  3. BMI = Body mass index
  4. Parametric data displayed as mean (1SD), non-parametric data displayed as median (IQR)
  5. * p value (< 0.05) for Spearmen correlation between EFV plasma concentrations and the presence of side effects (dependent variable)
  6. ** p value (< 0.05) for ANOVA analysis of EFV concentrations across genotypes for TT vs. GT/GG
  7. Side effects as per questionnaire score